Given the clinical heterogeneity in PTLD and the finding that anti-PAD2 antibodies associated with less severe disease in MS, we sought to define whether these autoantibodies associated with neurologic symptom severity in PTLD. Here, PADI2 is linked to myeloid sarcoma.